Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial

• Autores: Brigitte Koller, Beatrice Latal, Giancarlo Natalucci
• Localización: JAMA: the journal of the American Medical Association, ISSN 0098-7484, Vol. 315, Nº. 19, 2016, págs. 2079-2085
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • This randomized clinical trial assesses whether prophylactic early high-dose recombinant human erythropoietin (rhEPO) improves neurodevelopmental outcome for preterm infants at 2 years’ corrected age.